Nanobiotix S.A. (NBTX) Balance Sheet

The trajectory reveals a balance sheet that has become increasingly levered to debt rather than equity, as accumulated losses consistently consume more capital than the company raises through operations. The brief equity recovery from -$84.5M in 2025Q4 to -$33.4M in 2026Q2, alongside a cash injection that lifted liquidity from $52.8M to $110.8M, suggests a significant financing event occurred in early 2026, yet the fundamental problem of negative net worth persists. Investors should note that while the recent capital raise provided a temporary buffer, the underlying trajectory of persistent loss-making operations and rising liabilities means the balance sheet may remain structurally dependent on continued external financing.

The composition of Nanobiotix's debt burden appears increasingly necessity-driven rather than strategic: with operating losses exceeding $20M per quarter in recent periods, debt has been the primary mechanism funding continued research and collaboration spending. The current ratio improvement from 0.63 to 1.44 between 2025Q2 and 2026Q2 provides short-term relief, but this was achieved through a cash injection rather than operational cash generation. The absence of a meaningful equity buffer means any covenant constraints or refinancing demands from creditors could compress operating flexibility rapidly, particularly if collaboration revenue does not materialize as contracted.

The liquidity position improved materially on the surface, but the improvement appears to be a financing-driven event rather than an operational inflection. With quarterly operating cash outflows of approximately $22.3M and free cash flow burn of $23.0M in the most recent quarter, the $110.8M cash balance provides roughly five quarters of runway at current burn rates — before accounting for any debt servicing costs. The deferred revenue balance of $36.2M represents contracted cash already received, which may offer some downside protection, but investors should monitor whether this collaboration income continues to be recognized or whether contractual reversals like the 2024Q4 event recur.

The dramatic swings in retained earnings — including a $300M+ accumulated loss position at its peak — suggest either significant write-downs or recapitalization accounting events that have repeatedly reshaped the equity structure. The return to $0 in 2026Q2 alongside improved total equity implies a restructuring or debt-to-equity conversion occurred, but the fundamental reality remains that Nanobiotix's liabilities exceed its assets by $33.4M. For context, peer comparison shows Nanobiotix's current ratio of 1.44 sits between Novocure's 2.90 and Accuray's 1.65, but unlike those profitable or near-profitable peers, Nanobiotix's equity position reflects no cushion against further losses.